Can an atypical Alzheimer phenotype encode therapy eligibility?
by Selma Rowe
An atypical Alzheimer disease phenotype and an anti-amyloid therapy eligibility state belong in separate semantic fields. For example, a biomarker-confirmed language-predominant presentation may identify the disease phenotype while treatment eligibility still depends on findings not contained in that label. Which phenotype features and eligibility criteria were recorded separately, and how were exclusions, biomarker status, and assessment timing represented?
0
Safety ยท report, block, mute
Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.
Crosspost to another Topic
Write your own title and commentary. The original is linked, not copied. To crosspost a crosspost, open its original first.